Therapy & companion diagnostics ↗
Both involve Guardant Health, but screening and treatment selection are distinct uses and markets.
Evidence: Guardant Health ↗FDA ↗
Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗
Commercialization · TOPIC v4
Can Shield Bring More People into Colorectal Cancer Screening?
How far will broader coverage translate into new screening and diagnostic follow-up?
Read article → Shield: Can Expanded Coverage Lead to Screening and Diagnosis?
2026-09-23 09:45:04.320 UTC · Last recorded update
CURRENT READING
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
Recorded editorial state, not a maturity score
- Policy announcementRecorded
- January 2027 implementationScheduled
- Testing and paymentUnverified
- Follow-up colonoscopyUnverified
Additional source checked · v3 → 4
Added planned EviCore implementation; prior clinical-performance assessment is unchanged.
Permanent link to this revision ↗01 / WHAT WE TRACK
How far will broader coverage translate into new screening and diagnostic follow-up?
02 / EVIDENCE & TECHNOLOGY
Blood-based colorectal cancer screening / coverage / diagnostic follow-up
03 / EDITORIAL READING
How far will broader coverage translate into new screening and diagnostic follow-up?
04 / WHAT REMAINS UNKNOWN
A planned change reported by the company. The underlying policy and individual plan conditions have not been independently checked; this does not establish unconditional coverage or increased revenue.
05 / NEXT CHECK
Track implementation, tests and payments, participation by previously unscreened people, and completed follow-up colonoscopies separately.
tests / quarter (company-reported, approximate)
2025 Q216,000
2026 Q266,000
Two same-quarter observations a year apart; the path between them is unknown. This does not measure the effect of the September Carelon announcement. Ratio calculated from rounded disclosures.
Sources: Guardant Health ↗A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDBroader coverage combined with follow-up support may increase the number reaching diagnosis, not just the number tested.
What would change our view: Reconsider if wider eligibility does not increase new screening or completed follow-up colonoscopies.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsCOMPANYGuardant Health ↗
Provider of Shield and Guardant360 CDx; distinct products and uses.
Evidence: Guardant Health ↗FDA ↗
COMPANYCarelon Health Services ↗
Named in coverage announcement; policy text not independently checked.
Evidence: Guardant Health ↗
Related questions, optional follows
Map ↗Latest card updates
Latest 5 · editorial record dates- v4 · 2026-09-23 09:45:04.320 UTCAdditional source checked
Added planned EviCore implementation; prior clinical-performance assessment is unchanged.
Reading at the time: Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
- v3 · 2026-09-07 11:00:45.083 UTCAdditional source checked
Updated the related analysis after further source checks. This is not a newly announced trial or experiment.
Reading at the time: Testing and revenue have grown. Track previously unscreened participants, diagnostic follow-up and assay improvements separately.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Source-event timeline (different from editorial revisions)
- Recorded event
FDA approval date, distinct from the issuer announcement.
Sources: FDA ↗ - Recorded event
Q2 2026 test volumes disclosed by the company.
Sources: Guardant Health ↗ - Recorded event
Carelon coverage announced by the company.
Sources: Guardant Health ↗ - Scheduled
Announced effective date; implementation not yet confirmed.
Sources: Guardant Health ↗ - Recorded event
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
Sources: investors.guardanthealth.com ↗ - Scheduled
Scheduled effective date for EviCore guidelines.
Sources: investors.guardanthealth.com ↗
Historical events were assembled through source research. They do not imply the magazine tracked them at the time.
Background readings
Source dates and verification scope
NEJM原著 ↗
NEJM原著 · checked 2026-09-07 · primary
FDA審査資料 ↗
FDA審査資料 · checked 2026-09-07 · primary
FDA製品情報 ↗
FDA製品情報 · checked 2026-09-07 · primary
NCIの大腸がん検診解説 ↗
NCIの大腸がん検診解説 · checked 2026-09-07 · primary
中央病院の案内 ↗
中央病院の案内 · checked 2026-09-07 · primary
国立病院機構の任意検診案内 ↗
国立病院機構の任意検診案内 · checked 2026-09-07 · primary
国立がん研究センターのガイドライン ↗
国立がん研究センターのガイドライン · checked 2026-09-07 · primary
Second Quarter 2026 Financial Results ↗
Guardant Health · 2026-07-30 · issuer
Guardant Healthの発表 ↗
investors.guardanthealth.com · checked 2026-09-23 · public-source